Discover how everyday handling and storage can trigger ice damage in cryopreserved cell therapies, and what you can do to protect them.
Register here >>> hubs.ly/Q04C2M050

How do you overcome MSC variability to achieve reproducible, scalable results? Discover how a standardized UC-MSC source + defined expansion media can build a stronger foundation for MSC research.
Learn more >>> hubs.ly/Q04CQh590

Don’t miss our upcoming webinar with Miltenyi Biotec, ‘Automated HSC engineering process for HIV gene therapy: new process and preclinical data.’ Register now >>> hubs.ly/Q04BgsYw0

Could controlling ice recrystallization be the key to protecting cryopreserved cell therapies from temperature-driven damage and preserving post-thaw quality and function?
Learn more >>> hubs.ly/Q04C2LnB0

This interview gives expert guidance on cryopreservation strategy for cell therapy developers >>> hubs.ly/Q04zhdrg0

Dive into practical guidance for cell therapy developers navigating the complex intersection of cell biology, process development and regulatory requirements.

To celebrate 20 years of the journal Regenerative Medicine, Dusko Ilic reflects on the transformative moments that have defined regenerative medicine since 2006. Read here: hubs.ly/Q04CzdKZ0

Scalable, reproducible HSC gene therapy manufacturing matters. Join our webinar to discover lessons learned from automated processing and get new performance data and expert insights.
Join us: hubs.ly/Q04Bgsm90

Explore our new infographic on cell therapy cryopreservation >>> hubs.ly/Q04zh8qq0

Learn about:  
- how cryopreservation medium composition can affect therapeutic outcomes 
- the unique vulnerabilities of different cell type 
- regulatory considerations associated with reagent selection

In our latest In Focus feature, we're exploring cryopreservation >>> hubs.ly/Q04zh66B0

Check out our video, infographic and expert interview to explore the challenges, pitfalls and optimized strategies that can make the difference between therapeutic success and failure.

Ready to advance your HSC gene therapy production? Automated cell processing enhances quality and efficiency while helping to accelerate the delivery of gene-modified HSC therapies to patients.
Register >>> hubs.ly/Q04Bgs820

Don’t miss our upcoming webinar with Sartorius, ‘Building compliance into every step: validation across the fill & finish workflow.’ Register now >>> hubs.ly/Q04zcmTt0

We're celebrating 20 years of our partner journal, Regenerative Medicine! 

To mark this milestone, we're kicking off a series of specially commissioned anniversary content, starting with a retrospective article collection spanning 20 years of stem cell research! These articles of approaches within the field and celebrate the significant advances that have occurred over the journal’s lifetime. 

👉 Explore the collection: hubs.ly/Q04B5-j50 

Keep an eye on the anniversary homepage where we'll be sharing more retrospective content, expert interviews and exclusive features as we continue to celebrate two decades of Regenerative Medicine. 

👉 Visit the anniversary homepage: hubs.ly/Q04B5-mM0 

#20YearsofRegenerativeMedicine

Discover why robust validation strategies are critical for ensuring compliance and minimizing risk.
Register today >>> hubs.ly/Q04zclFG0

PromoCell experts Iris Bischoff-Kont and Laura Aschmis share their insights on developing robust cryopreservation strategies, including the hidden pitfalls of relying solely on viability data and the specific vulnerabilities of stem and primary cells >>> hubs.ly/Q04zhccP0

Are your early cryopreservation decisions setting you up for success, or future challenges?

Cryopreservation decisions made during early development have lasting consequences for therapeutic quality, manufacturing scale-up and global distribution capabilities.

This infographic derations to help you build a cryopreservation strategy >>> hubs.ly/Q04zh7P40

Our new In Focus video breaks down why cryopreservation is a critical process step in cell therapy development and how optimized approaches can improve cell quality, streamline manufacturing and support clinical and commercial success >>> hubs.ly/Q04zh4X90

What's inside our cardiac regeneration eBook?
🔬Human-relevant research models
💉Innovative therapeutic strategies
⚛️Biomaterial and scaffold innovations
👩‍⚕️Translational insights

Download your free copy today >>> hubs.ly/Q04xwCy-0

We're counting down the days to ESGCT 2026!

Come and find us at booth I-08 to chat the team and enter our prize draw for a chance to win an iPad! 📱✨

In the meantime, with so much on the agenda, we've picked out the key themes an sessions we're most excited about >>> hubs.ly/Q04zhtCM0

📖Get your copy: hubs.ly/Q04xwBz30

Bridging the gap between lab and clinic, our latest eBook on cardiac regeneration offers valuable insights for researchers at every stage. From developing preclinical models to advancing therapeutic candidates toward clinical application, ontent and expert perspectives shaping the future of cardiovascular medicine.

📖Editor’s picks: Journal highlights >>>

Our Commissioning Editor Jasmine Hagan spotlights her top papers from recent issues, featuring cutting-edge developments that address significant clinical challenges with novel cell therapies, advanced manufacturing techniques, and sustainable biomaterials.

From engineered cardiac patches to cell therapies using mesenchymal and induced pluripotent stem cells >>> hubs.ly/Q04xwBlT0

Our latest eBook explores innovative therapeutic strategies addressing the heart's limited regenerative capacity. Get your free copy!

What if muscle cells hold the key to stopping fibrosis? Cook MyoSite's latest research uncovers the cellular crosstalk that keeps damaged muscle from turning into fat and scar tissue. This discovery could transform treatment for muscular dystrophy and volumetric muscle loss. per now >>> hubs.ly/Q04xlBwJ0

Have you downloaded the whitepaper ‘Cellular crosstalk in muscle tissue regeneration: lessons from FAP differentiation’?

Explore research from Cook MyoSite examining the crosstalk between skeletal muscle progenitor cells and fibro-adipogenic progenitor cells that suggests that lthy myotubes may help keep FAP cells in a less differentiated state.  

Learn more here >>>hubs.ly/Q04xlByc0

Advancing cardiac regenerative medicine requires human-relevant research models that accurately replicate the heart's complex cellular interactions. Our latest eBook features cutting-edge tools including cardiac spheroids that mimic the beating heart and endothelial cell assays . Download now >>> hubs.ly/Q04xwz-Z0

High translational failure rates, oversimplified in vitro systems, and animal models that don't capture the complexity of human tumor biology are driving a fundamental shift in how we evaluate immune cell therapies before they reach patients. 

Discover how preclinical models are gap >>> hubs.ly/Q04vFxW_0

From selecting the right model system to incorporating relevant microenvironmental factors, multiple considerations shape the quality and interpretability of your data.

This infographic outlines six essential considerations to guide your preclinical model design, helping you relevant systems that support robust immune cell therapy development >>> hubs.ly/Q04vFQKs0

Find out how a novel gene activation platform, half the size of its CRISPR-based counterpart, could revolutionize the deliverability of gene therapies that target gene expression >>> hubs.ly/Q04x7LYc0

🚨Don't miss our In Focus exploring how preclinical model systems can be used to support the development of immune cell therapies >>> hubs.ly/Q04vFPsP0

What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04x6Pkq0

> uniQure submitted regulatory applications for its Huntington’s disease gene therapy in the US and UK
> Bristol Myers Squibb announced positive topline results from the registrational Phase II trial rapy for quadruple-class exposed relapsed and refractory multiple myeloma
> EpilepsyGTx and Viralgen have entered into a partnership to develop an epilepsy gene therapy

In our latest article, explore in vivo CAR-T programs currently in clinical trials and several that have been acquired by major pharmaceutical companies >>> hubs.ly/Q04x0FjX0

As immune cell therapies move into more complex solid tumor settings, why is preclinical model design becoming more important? 

Three experts answer this question and outline a path forward to build preclinical platforms that better predict clinical outcomes and accelerate the e immune cell therapies. 

Read their insights here >>> hubs.ly/Q04vFwjX0

Learn how to design preclinical models that accurately reflect tumor-immune interactions and support the development of immune cell therapies for solid tumors in this infographic >>> hubs.ly/Q04vDSsX0

Discover how researchers are building tumor-immune model systems that better predict clinical outcomes and accelerate immune cell therapy development in our latest In Focus >>> hubs.ly/Q04vFsNV0

The cell and gene therapy sector has seen significant mergers and acquisitions activity over the past year. In this article, we explored billion-dollar acquisitions, including in vivo CAR-T programs, epilepsy cell therapies, and in vivo gene replacement systems – and the year ergers and acquisitions do you think are next?

Read our latest article here: hubs.ly/Q04vb7KN0

White Paper: Myotubes inhibit and regulate FAP-to-adipocyte differentiation in vitro 

Download now to read research from Cook MyoSite examining the crosstalk between skeletal muscle progenitor cells and fibro-adipogenic progenitor cells.

>>>  hubs.ly/Q04rXMg10

Have you downloaded 'White Paper: Myotubes negatively regulate fap-to-adipocyte differentiation in vitro' yet? 

Don't miss out on findings that suggest signals from healthy myotubes may help keep fibro-adipogenic progenitor cells in a less differentiated state. 

Download now zYtO

What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04tKhrm0

> Sangamo Therapeutics auctioned off its main assets
> Andelyn Biosciences and Queen’s University partnered to advance a lysosomal storage disorder gene therapy program
> The FDA approved Ultragenytherapy for glycogen storage disease type 1a (GSD1a)

This Cook MyoSite White Paper reveals how mature myotubes shift adipocytes toward a more immature, white-fat-like phenotype rather than the brown/beige fat signature seen when FAPs differentiate alone offering potential mechanistic leads for muscle disease therapies. 

Learn more fS7qho3Av

Drawing on expert perspectives from cell and gene therapy, health technology commercialization and European access, Ry Leahy's latest column uses Greece as a case study for what it takes to deploy advanced therapies beyond the obvious centers.

"The next test for cell and gene ether it can work in the best-resourced places in the world; it is whether the field can build systems that allow these breakthroughs to reach the patients who live beyond them."

Read the full column here: hubs.ly/Q04syL2d0

Fill and finish in #viral #vector manufacturing is more than just the final stage. In this infographic, explore the unique challenges that emerge during fill and finish and the strategies being used to overcome them. 

Download the infographic, in partnership with > hubs.ly/Q04pN7Y-0

New Cook MyoSite research examines the crosstalk between skeletal muscle progenitor cells and fibro-adipogenic progenitor cells—a relationship central to muscle healing after injury and in diseases like Duchenne Muscular Dystrophy and volumetric muscle loss. 

Read the White .co/P8sS58he9C

From silencing disease-causing genes to restoring enzyme function and resetting retinal gene networks, three gene therapies in clinical trials are demonstrating how genetic medicine could transform outcomes for patients with inherited muscular dystrophy, metabolic disorders and Read about them here >>> hubs.ly/Q04rQLhW0

In this video, as part of our In Focus on fill and finish, we explore the critical risks in the final stage of viral vector manufacturing and the importance of getting each step right to maintain product integrity >>> hubs.ly/Q04pM_MP0

What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04qDxDn0

Tempest Therapeutics and Hebei Senlang Biotechnology have collaborated to develop an in vivo dual-targeting CAR-T candidate

Repligen Corporation is to acquire BioLife Solutions for approximately enterprise value

Immitra Bio has secured US$3 million in pre-seed funding to advance its scalable in vivo gene editing platform.

In this feature, we explore the integration of artificial intelligence into regenerative medicine, showcasing four ways this advanced technology is being harnessed in the field.

Have a read here: hubs.ly/Q04qsc_n0

Behind every safe and effective healthcare product stands the critical work of regulatory affairs professionals. In this column, Patrice Faloye, a regulatory affairs professional with a breadth of experience, shares her journey into regulatory affairs, discussing the pivotal career path. She also offers valuable insights and practical advice on the essential steps aspiring professionals can take to successfully break into this vital and growing field. Read now: hubs.ly/Q04q6hdg0

What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04pHJ3Y0

This week:

>/ Apertura Gene Therapy announced that it has entered into a Cooperative Research and Development Agreement to evaluate the systemic delivery of an investigational gene therapy for NieC1

>/ Scripps Research presented encouraging interim clinical data from its Phase I/IIa assessing a stem cell therapy for Parkinson’s disease at ISSCR

>/ The FDA expanded the age range of Vertex Pharmaceutical’s Casgevy to include younger patients

Overcome variability challenges when transitioning autologous CAR-T from clinical to commercial scale using reproducible, closed-system workflows that maintain product quality while enabling throughput. In this poster, @thermofisher presents the data to back it up >>> hubs.ly/Q04lyNC00

What's the latest in cell and gene therapy? Catch up here: hubs.ly/Q04p02j40

This week:
> The FDA cleared an IND application for CoRegen, Inc.'s adoptive cell therapy, CRG-150

> Epicrispr Biotechnologies announced the completion of enrollment and dosing in the dose-es first-in-human clinical trial assessing EPI-321 for facioscapulohumeral muscular dystrophy

> RoosterBio and Applied StemCell, Inc. have entered into a strategic partnership to develop and commercialize scalable iPSC-based bioprocess solutions

@SartoriusGlobal are at #ISSCR2026, ready to talk about the launch of their Nutri3D hiPSC ACF medium for iPSC cultures. Visit booth #712 learn more and to meet Maya, Noushin and the rest of the team!

@SartoriusGlobal are at #ISSCR2026, ready to talk about the launch of their Nutri3D hiPSC ACF medium for iPSC cultures. Visit booth #712 learn more and to meet Maya, Noushin and the rest of the team!